Stealth BioTherapeutics announced the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease (RPD) designation for elamipretide for the treatment of Barth syndrome.
Renal pelvis dilatation (RPD) at the fetal anomaly scan (FAS) and persistent dilatation in later pregnancy or postpartum is associated with an increased risk for hospital admission in early childhood...